SynthesisMolecular psychiatry2026
A systematic review and meta-analysis of the auditory steady-state response in schizophrenia, bipolar disorder, and autism spectrum disorder.
Synthesis in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cognitive pleiotropy reveals disorder-specific and shared biology for schizophrenia and bipolar disorder.medRxiv : the preprint server for health sciences · 2026Article
- Phase delay and neural dyssynchrony of the 40-Hz auditory steady-state response in mood and psychotic disorders.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe 40-Hz auditory steady-state response (ASSR) is a potential biomarker for schizophrenia (SZ), bipolar disorder (BD), and autism spectrum disorder (ASD). However, the specific differences in ASSR across these disorders remain unclear. Moreover, the neurophysiological characteristics of the stimulation frequency in ASSR have not been fully elucidated. Hence, we conducted meta-analyses to comprehensively analyze 20-Hz, 40-Hz, and 80-Hz ASSR in individuals with SZ, BD, and ASD.
methodsWe included the studies published until January 2025, identified through a literature search in PubMed and the reference lists of relevant studies. We analyzed 52 studies, including 2116 patients with SZ, 271 individuals at clinical high-risk for psychosis (CHR-P), 110 first-degree relatives of patients with SZ (FDR-SZ), 294 patients with BD, 117 patients with ASD, and 2758 healthy controls (HC).
resultsThe analyses indicated pronounced reductions in power and inter-trial phase coherence (ITPC) of 40-Hz ASSR in SZ, BD, and power reduction in ASD compared with HC. In addition, reduced power and ITPC were also observed in 40-Hz ASSR in FDR-SZ but not in CHR-P. Power reductions in 80-Hz ASSR were noted in individuals with SZ, while ITPC of 20-Hz ASSR was reduced in the SZ group but not in the BD group.
conclusionsThese findings indicate that 40-Hz ASSR serves as a potential biomarker for psychotic disorders, whereas deficits at 20 Hz and 80 Hz may be specific to schizophrenia, reflecting distinct neural dysfunctions across diagnostic categories. Further studies are warranted to confirm these results.
Indexed as
Identifiers
41634135What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.